

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	OCT 04	Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/Cplus.
NEWS 4	OCT 21	CA/Cplus kind code changes for Chinese patents increase consistency, save time
NEWS 5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 7	NOV 03	New format for Korean patent application numbers in CA/Cplus increases consistency, saves time.
NEWS 8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 9	NOV 18	PROUSDDB and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS 11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS 12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS 13	DEC 18	ReaxysFile available on STN
NEWS 14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in Cplus
NEWS 16	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS 17	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS 18	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS 19	JAN 28	CABA will be updated weekly
NEWS 20	FEB 23	PCTFULL file on STN completely reloaded
NEWS 21	FEB 23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS 22	FEB 25	LPCI will be replaced by LDPCI
NEWS 23	MAR 07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN

NEWS EXPRESS 17 DECEMBER 2010 CURRENT WINDOWS VERSION IS V8.4.2 .1,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE
ENTRY SESSION
0.23 0.23
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 MAR 2011 HIGHEST RN 1273386-30-3
DICTIONARY FILE UPDATES: 31 MAR 2011 HIGHEST RN 1273386-30-3

CAS Information Use Policies apply and are available at: www.cas.org/InformationUsePolicies.aspx

<http://www.cas.org/legal/inforpolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stndgen/stndoc/properties.html>

=> s 89-25-8/rn
1.1 1 89-25-8/RN

⇒ d. 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2011 ACS on STN
RN 89-25-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Pyrazolin-5-one, 3-methyl-1-phenyl- (8CI)
OTHER NAMES:
CN 1-Phenyl-3-methyl-1H-4,5-dihydropyrazol-5-one

CN 1-Phenyl-3-methyl-2-pyrazolin-5-one
 CN 1-Phenyl-3-methyl-5-oxopyrazole
 CN 1-Phenyl-3-methyl-5-pyrazolinone
 CN 1-Phenyl-3-methyl-5-pyrazolone
 CN 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one
 CN 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one
 CN 3-Methyl-1-phenyl-1H-pyrazol-5-one
 CN 3-Methyl-1-phenyl-2-pyrazolin-5-one
 CN 3-Methyl-1-phenyl-2-pyrazoline-5-one
 CN 3-Methyl-1-phenyl-4,5-dihydropyrazol-5-one
 CN 3-Methyl-1-phenyl-4,5-dihydropyrazole-5-one
 CN 3-Methyl-1-phenyl-5-pyrazolone
 CN 3-Methyl-1-phenylpyrazol-5(4H)-one
 CN 3-Methyl-1-phenylpyrazolin-5-one
 CN 5-Methyl-2-phenyl-2H-pyrazol-3(4H)-one
 CN 5-Methyl-2-phenylpyrazol-3-one
 CN C.I. Developer 1
 CN Developer Z
 CN Edaravone
 CN MCI 186
 CN Methylphenylpyrazolone
 CN NCI-C 03952
 CN Norantipyrine
 CN Norphenazone
 CN NSC 12
 CN NSC 26139
 CN NSC 2629
 CN Radicut
 DR 12235-58-4, 62495-97-0, 115566-83-1, 72134-66-8, 52224-17-6, 206195-95-1
 MF C10 H10 N2 O
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
 CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, DDFU,
 DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IMSRESEARCH,
 IPA, MEDLINE, MRCK*, MSDS-OHS, PIRA, PS, REAXYSFILE*, RTECS*, SPECINFO,
 TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD, VETU
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3282 REFERENCES IN FILE CA (1907 TO DATE)
 77 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3315 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE ENTRY	TOTAL SESSION
2.66	2.89

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Apr 2011 VOL 154 ISS 15
FILE LAST UPDATED: 31 Mar 2011 (20110331/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 11
L2      3315 L1

=> s 12 and percutaneous
      13590 PERCUTANEOUS
L3      4 L2 AND PERCUTANEOUS

=> dup rem 13
PROCESSING COMPLETED FOR L3
L4      4 DUP REM L3 (0 DUPLICATES REMOVED)
```

```
=> d 14 1-4 ibib abs

L4  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER:  2007:868095  CAPLUS
DOCUMENT NUMBER:  147:219409
TITLE:  Percutaneous absorption-type chemical agents
        containing alkali ion water
INVENTOR(S):  Okajima, Masahiro; Ishii, Fumiyoishi
PATENT ASSIGNEE(S):  A.I. System Products Corp., Japan
SOURCE:  Jpn. Kokai Tokkyo Koho, 20pp.
        CODEN: JKXXAF
DOCUMENT TYPE:  Patent
LANGUAGE:  Japanese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
JP 2007197349	A	20070809	JP 2006-16666	20060125

PRIORITY APPLN. INFO.:

JP 2006-16666

20060125

AB The chemical agents contain skin-penetrating alkali ion water as a percutaneous absorption enhancer. Preferably, the alkali ion water is produced by deoxygenation, electrolysis, and stabilization under ≥ 4 kg/cm² pressure of pure water. The amts. of tramadol-HCl penetrated through rat skin, artificial cultured skin, or EVA membrane were higher in 50% electrolyzed alkali ion water than in a phosphate buffer. A cosmetic lotion containing alkali ion water (containing neg. ions), 1,3-butylene glycol, ethoxylated sunflower oil, polyoxyethylene oleyl ether, and EtOH was formulated. The ion water (at 1000-10,000 ppm) showed no acute toxicity to medaka (*Oryzias latipes*).

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:451191 CAPLUS

DOCUMENT NUMBER: 142:487534

TITLE: Percutaneous absorption type cerebral protective agent

INVENTOR(S): Mori, Jun; Horiuchi, Tamaki; Yama, Seijiro; Waki, Hitomi; Shimada, Shingo; Hashitani, Hitomi

PATENT ASSIGNEE(S): Lead Chemical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 27 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046680	A1	20050526	WO 2003-JP14362	20031112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003280739	A1	20040606	AU 2003-280739	20031112
CA 2546064	A1	20050526	CA 2003-2546064	20031112
EP 1685837	A1	20060802	EP 2003-772698	20031112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
CN 1878549	A	20061213	CN 2003-80110679	20031112
CN 100528153	C	20090819		
US 20070148217	A1	20070628	US 2006-579055	20060511
IN 2006DN02817	A	20070803	IN 2006-DN2817	20060518
KR 2006123295	A	20061201	KR 2006-7011405	20060609
KR 1008052	B1	20110113		

PRIORITY APPLN. INFO.: WO 2003-JP14362 A 20031112

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A percutaneous absorption type cerebral protective agent is characterized by comprising a base and 0.1 to 30 % either 3-methyl-1-phenyl-2-pyrazolin-5-one or a medically acceptable salt thereof contained as an active ingredient in the base.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:412806 CAPLUS

DOCUMENT NUMBER: 140:395557

TITLE: Percutaneous absorption preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one

INVENTOR(S): Mori, Jun; Horiuchi, Tamaki; Yama, Seijiro; Waki, Hitomi; Shimada, Shingo; Hashitani, Hitomi

PATENT ASSIGNEE(S): Lead Chemical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 24 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041270	A1	20040521	WO 2002-JP11518	20021105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504873	A1	20040521	CA 2002-2504873	20021105
AU 2002344454	A1	20040607	AU 2002-344454	20021105
EP 1559426	A1	20050803	EP 2002-779994	20021105
EP 1559426	B1	20110209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1694699	A	20051109	CN 2002-829849	20021105
CN 100372531	C	20080305		
JP 4487258	B2	20100623	JP 2004-549555	20021105
AT 497764	T	20110215	AT 2002-779994	20021105
KR 892813	B1	20090410	KR 2005-7007797	20050502
US 20050266062	A1	20051201	US 2005-533534	20050622
HK 1084588	A1	20080822	HK 2006-104915	20060425

PRIORITY APPLN. INFO.: WO 2002-JP11518 W 20021105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Disclosed are percutaneous absorption prepsns. (optionally being in the form of patches) which contain as the active ingredient from 0.1 to 30% by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one or its pharmaceutically acceptable salt in an appropriate base, for example, an aqueous base or a rubber base. These prepsns. (or patches) are excellent percutaneous absorption prepsns. (or percutaneous absorption patches) showing a high percutaneous absorbability of the active ingredient and little skin irritation. A composition A containing sodium polyacrylate 5, starch acrylate 6, talc 12, concentrate glycerin 29.1 parts, a composition B containing tartaric acid 2.3 and water 30 parts, and a composition C containing 3-methyl-1-phenyl-2-pyrazolin-5-one 3, N-methyl-2-pyrrolidone 8, crotamiton 2 parts were mixed, and then combined with Me acrylate-2-ethylhexyl acrylate copolymer emulsion 2.5, and aluminum hydroxide gel 0.1 parts. The mixed composition was applied on a polyester nonwoven fabric base to obtain a transdermal patch of the present invention.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2004:310105 CAPLUS
 DOCUMENT NUMBER: 140:297521
 TITLE: Pyrazolone derivatives for treatment and/or prevention
 of arterial wall failure
 INVENTOR(S): Tanaka, Takayuki; Mori, Tatsuhiko
 PATENT ASSIGNEE(S): Mitsubishi Welpharma Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004115505	A	20040415	JP 2003-311057	20030903
US 20040254234	A1	20041216	US 2003-643404	20030818
US 7312239	B2	20071225		

PRIORITY APPLN. INFO.: JP 2002-258503 A 20020904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:297521

AB The invention provides pyrazolone derivs., e.g.
 3-methyl-1-phenyl-2-pyrazolin-5-one (Edaravone) for treatment and/or
 prevention of arterial wall failure, e.g. coronary restenosis after
 percutaneous transluminal coronary angioplasty (PTCA) and coronary
 artery bypass graft (CABG) surgery. The effect of Edaravone on arterial
 neo-intima in rabbits fed a high-cholesterol diet was examined

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011)

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
 L1 1 S 89-25-8/RN

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
 L2 3315 S L1
 L3 4 S L2 AND PERCUTANEOUS
 L4 4 DUP REM L3 (0 DUPLICATES REMOVED)

=> s 12 and cerebral
 130922 CEREBRAL
 L5 285 L2 AND CEREBRAL

=> s 15 and (crotamiton)
 406 CROTAMITON
 1 CROTAMITONS
 406 CROTAMITON
 (CROTAMITON OR CROTAMITONS)
 L6 1 L5 AND (CROTAMITON)

=> d 16 ibib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2006:100738 CAPLUS
 DOCUMENT NUMBER: 144:198849
 TITLE: Novel dosage form comprising modified-release and
 immediate-release active ingredients

INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;
 Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.
 Ser. No. 630,446.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 20040096499	A1	20040520	US 2003-630446	20030729
PRIORITY APPLN. INFO.:			IN 2002-MU697	A 20020805
			IN 2002-MU699	A 20020805
			IN 2003-MU80	A 20030122
			IN 2003-MU82	A 20030122
			US 2003-630446	A2 20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared. The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011)

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
 L1 1 S 89-25-8/RN

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
 L2 3315 S L1
 L3 4 S L2 AND PERCUTANEOUS
 L4 4 DUP REM L3 (0 DUPLICATES REMOVED)
 L5 285 S L2 AND CEREBRAL
 L6 1 S L5 AND (CROTAMITON)

=> s 15 and crotamiton
 406 CROTAMITON
 1 CROTAMITONS
 406 CROTAMITON
 (CROTAMITON OR CROTAMITONS)
 L7 1 L5 AND CROTAMITON

=> s 15 and "lactic acid"
 135999 "LACTIC"
 37 "LACTICS"
 136015 "LACTIC"

("LACTIC" OR "LACTICS")
5261547 "ACID"
1809752 "ACIDS"
5821043 "ACID"
 ("ACID" OR "ACIDS")
119226 "LACTIC ACID"
 ("LACTIC" (W) "ACID")
L8 1 L5 AND "LACTIC ACID"

=> d 18 ibib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1997:447450 CAPLUS
DOCUMENT NUMBER: 127:120286
ORIGINAL REFERENCE NO.: 127:23164h,23165a
TITLE: In vitro evaluation of metabolic change in forebrain
 ischemia model of rat using proton magnetic resonance
 spectroscopy
AUTHOR(S): Tanaka, Naruhiko
CORPORATE SOURCE: Sch. Med., Hokkaido Univ., Sapporo, 060, Japan
SOURCE: Hokkaido Igaku Zasshi (1997), 72(3), 329-342
CODEN: HOIZAK; ISSN: 0367-6102
PUBLISHER: Hokkaido Igakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Metabolic disruption resulted from cerebral ischemia and
post-ischemic reperfusion injury was studied using proton magnetic
resonance spectroscopy (1H MRS). We also analyzed the effect of
3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) which can scavenge free
radicals induced in the brain tissue due to ischemic-reperfusion in this
experiment. The ischemic model was produced using rat forebrain ischemic model
(Pulsinelli's 4 vessels occlusion model). Postischemic reperfusion was
also induced by the re-opening of the occluded common carotid arteries.
The occluded time was 30 min and reperfusion time 0, 10, 30, 60 min. We
obtained the specimens in the cortex under microwave fixation. Choline
and acetate increased during ischemia and gradually decreased during
reperfusion period. These 2 signals seen in 1H MRS are supposed to
represent cell membrane components (products) and the increase of these
signals after reperfusion seems to be related to the postischemic
reperfusion injury due to the explosive increase of free radicals.
Lactate, which is induced by anaerobic glycolysis, increased during
ischemia and promptly disappeared after reperfusion. The treatment of
preischemic administration of MCI-186 significantly suppressed increases
of choline and acetate. As far as lactate is concerned, postischemic
administration of this drug significantly reduced its increase at the
point of reperfusion. Our results suggest that MCI-186 attenuates changes
induced by ischemic-reperfusion injury in membranous metabolism, probably due
to its free radical scavenging action.

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011)

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
L1 1 S 89-25-8/RN

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
L2 3315 S L1
L3 4 S L2 AND PERCUTANEOUS
L4 4 DUP REM L3 (0 DUPLICATES REMOVED)
L5 285 S L2 AND CEREBRAL

L6 1 S L5 AND (CROTAMITON)
L7 1 S L5 AND CROTAMITON
L8 1 S L5 AND "LACTIC ACID"

=> s 12 and "lactic acid"
135999 "LACTIC"
37 "LACTICS"
136015 "LACTIC"
("LACTIC" OR "LACTICS")
5261547 "ACID"
1809752 "ACIDS"
5821043 "ACID"
("ACID" OR "ACIDS")
119226 "LACTIC ACID"
("LACTIC"(W)"ACID")
L9 15 L2 AND "LACTIC ACID"

=> s 19 and crotamiton
406 CROTAMITON
1 CROTAMITONS
406 CROTAMITON
(CROTAMITON OR CROTAMITONS)
L10 0 L9 AND CROTAMITON

=> s 19 and isopropanol
45641 ISOPROPANOL
45 ISOPROPANOLS
45669 ISOPROPANOL
(ISOPROPANOL OR ISOPROPANOLS)
L11 1 L9 AND ISOPROPANOL

=> d 111 ibib abs

L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2002:408993 CAPLUS
DOCUMENT NUMBER: 136:406574
TITLE: Hair dye compositions containing
1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane and an
additional oxidation base and a coupler
INVENTOR(S): Audoussel, Marie-pascale
PATENT ASSIGNEE(S): L'oreal S.A., Fr.
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U. S.
Ser. No. 335,742.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020062529	A1	20020530	US 2001-829433	20010410
FR 2779948	A1	19991224	FR 1998-7793	19980619
FR 2779948	B1	20040423		
US 20030200614	A1	20031030	US 1999-335742	19990618
PRIORITY APPLN. INFO.:			FR 1998-7793	A 19980619
			US 1999-335742	A2 19990618

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:406574

AB The invention relates to a composition for the oxidation dyeing of keratin
fibers,
containing a first oxidation base chosen from

1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane and acid-addition salts thereof, at least one second selected oxidation base and at least one coupler; as well as to the oxidation dyeing process using this composition and multicompartiment devices/kits. Thus, a composition contained
1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane tetrahydrochloride monohydrate 0.39, p-phenylenediamine 0.162, 5-N-(β -hydroxyethyl)amino-2-methylphenol (coupler) 0.498, EtOH 18, sodium metabisulfite (35% aqueous solution) 0.68, pentasodium diethylenetriaminopentaacetate 1.1, 20% NH3 solution
10.0 and water to 100 g.

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011)

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
L1 1 S 89-25-8/RN

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
L2 3315 S L1
L3 4 S L2 AND PERCUTANEOUS
L4 4 DUP REM L3 (0 DUPLICATES REMOVED)
L5 285 S L2 AND CEREBRAL
L6 1 S L5 AND (CROTAMITON)
L7 1 S L5 AND CROTAMITON
L8 1 S L5 AND "LACTIC ACID"
L9 15 S L2 AND "LACTIC ACID"
L10 0 S L9 AND CROTAMITON
L11 1 S L9 AND ISOPROPANOL

=> s l2 and (topical or dermal)

64918 TOPICAL
51 TOPICALS
64939 TOPICAL
(TOPICAL OR TOPICALS)
21918 DERMAL
L12 9 L2 AND (TOPICAL OR DERMAL)

=> dup rem l12

PROCESSING COMPLETED FOR L12

L13 9 DUP REM L12 (0 DUPLICATES REMOVED)

=> d l13 1-9 ibib abs

L13 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2011:110389 CAPLUS
DOCUMENT NUMBER: 154:166429
TITLE: Moisturizing retinol composition
INVENTOR(S): Kunin, Audrey
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20110020414	A1	20110127	US 2010-844368	20100727
PRIORITY APPLN. INFO.:			US 2009-228788P	P 20090727

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB An anti-aging composition is provided that contains high potency retinol along with anti-irritant properties. In particular, an anti-aging composition includes a base, from about 0.001% to 20.0 vol % retinol, at least one anti-irritant agent, at least one antioxidant, at least one anti-inflammatory agent, and a moisturizing complex. In one non-limiting illustration, the anti-aging composition contains about 1.0 vol % retinol, *Plantago lanceolata*, *Hypericum perforatum* leaf extract, phytosphingosine, *Leontopodium alpinum* extract, *Glycyrrhiza glabra* root extract, *Sambucus nigra* flower extract, nordihydroguaiaretic acid, oleanolic acid, *Spiraea ulmaria* flower extract, *Evodia rutaecarpa* fruit extract, *Boswellia serrata* extract, and additives.

L13 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1433641 CAPLUS

DOCUMENT NUMBER: 153:610664

TITLE: Steroid containing composition in combination with antioxidant or inhibitor of forkhead signaling and therapeutic uses thereof

INVENTOR(S): Hulley, Philipa; Poulsen, Raewyn; Carr, Andrew

PATENT ASSIGNEE(S): Isis Innovation Limited, UK

SOURCE: PCT Int. Appl., 46pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010131038	A2	20101118	WO 2010-GB50776	20100512
WO 2010131038	A3	20101006		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: GB 2009-8174 A 20090513

AB The present invention provides the use of a steroid in combination with an anti-oxidant or an inhibitor of forkhead signaling, in particular, for the treatment, amelioration or prevention of tissue degeneration and/or pain and/or inflammation and/or for facilitating tissue repair. The invention also provides a composition comprising a steroid and an anti-oxidant or an inhibitor of forkhead signaling.

L13 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1102644 CAPLUS

DOCUMENT NUMBER: 153:368419

TITLE: Topical skin care composition containing an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant

INVENTOR(S): Kunin, Audrey

PATENT ASSIGNEE(S): DERMAdoctor, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 7 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20100221245	A1	20100902	US 2009-395251	20090227
PRIORITY APPLN. INFO.:			US 2009-395251	20090227

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is directed to a topical skin care composition. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the composition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The antibacterial agent may be benzoyl peroxide. Formulation of a topical pharmaceutical containing 0.5% benzoyl peroxide was disclosed.

L13 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:1295413 CAPLUS

DOCUMENT NUMBER: 1461135359

TITLE: Edaravone protects the vestibular periphery from free radical-induced toxicity in response to perilymphatic application of (\pm) - α -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid

AUTHOR(S): Shimogori, Hiroaki; Takemoto, Tsuyoshi; Mikuriya, Takefumi; Yamashita, Hiroshi

CORPORATE SOURCE: Department of Otolaryngology, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan

SOURCE: European Journal of Pharmacology (2007), 554(2-3), 223-228

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Intracochlear infusion of (\pm) - α -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) was performed with a syringe pump in guinea pigs, and peripheral vestibular dysfunction was induced. Animals were administered edaravone systemically or topically. In the systemic application group, animals were administered edaravone once a day for 7 days after AMPA infusion. In the topical application group, edaravone-soaked gelfoam was placed on the round window membrane just after, 12 h after or 24 h after AMPA infusion. Spontaneous nystagmus was observed after AMPA infusion. Immunohistochem. for 4-hydroxy-2-nonenal (4-HNE), a marker of free radical-induced lipid peroxidn., was performed 24 h after AMPA infusion. In addition, caloric tests were performed to evaluate vestibular function 1 wk after AMPA infusion. Animals in both groups showed decreased spontaneous nystagmus, but results were not significant. Animals treated topically with edaravone within 12 h of AMPA infusion showed normal morphol. of the ampullar sensory epithelia of the lateral semicircular canals and showed a good response to the caloric tests. 4-HNE immunoreactivity in the sensory epithelia was very low in these animals. In contrast, untreated animals and animals treated with edaravone systemically or topically 24 h after AMPA infusion showed morphol. hair cell damage, reduced caloric response and remarkable 4-HNE immunoreactivity in the sensory epithelia. These results indicate that topical application of edaravone within 12 h after damage protects the vestibular periphery from free radical-induced toxicity in response to intracochlear infusion of AMPA.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2007:160167 CAPLUS
DOCUMENT NUMBER: 146:493375
TITLE: A study for the influence of inner ear application of edaravone
AUTHOR(S): Orita, Hiroshi; Shimogori, Hiroaki; Takeno, Kenji;
Mikuriya, Takefumi; Yamashita, Hiroshi
CORPORATE SOURCE: Dep. Otolaryngology, Sch. Med., Yamaguchi University,
Ube, 755-8505, Japan
SOURCE: Otology Japan (2006), 16(5), 617-621
CODEN: OTJAEW; ISSN: 0917-2025
PUBLISHER: Nippon Jika Gakkai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB The aim of study was to evaluate the safety of edaravone applied into the inner ear of the guinea pig, as assessed physiol. and morphol. Edaravone (6 mg/mL)-soaked Gelform pieces were put on the round window membrane of guinea pigs in the right ear. Before and 7 days after treatment, each animal was studied by auditory brainstem response (ABR) and caloric test. After physiol. examination, ampulla of the lateral semicircular canal, utricle and cochlea were investigated morphol. No significant ABR threshold shift was observed in the animals between before and 7 days after treatment. No significant difference was found in the caloric response time between the right and left side 7 days after treatment. Seven days after treatment, no obvious morphol. change in the vestibular and cochlear endorgans was observed in all animals. These results suggested that the topical application of edaravone to the inner ear inducer no obvious tissue damage physiol. morphol.

L13 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:307626 CAPLUS
DOCUMENT NUMBER: 140:297555
TITLE: Pyrazolone derivatives for treatment of skin burns
INVENTOR(S): Shinosawa, Yotaro
PATENT ASSIGNEE(S): Mitsubishi Welpharma Co., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004115508	A	20040415	JP 2003-313482	20030905
PRIORITY APPLN. INFO.:			JP 2002-260961	A 20020906

OTHER SOURCE(S): MARPAT 140:297555
AB The invention provides pyrazolone derivs., e.g. 3-methyl-1-phenyl-2-pyrazolin-5-one (Edaravone), for improving function of burned skin. The effect of Edaravone on burned skin function in rats with hot-water burn was examined

L13 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:271495 CAPLUS
DOCUMENT NUMBER: 140:292660
TITLE: Transdermal or transmucosal preparations containing 3-methyl-1-phenyl-2-pyrazolin-5-one (salt) for treatment of free radical-caused diseases
INVENTOR(S): Mizuno, Keizo; Sato, Toshiaki; Matsuo, Yumi
PATENT ASSIGNEE(S): Mikasa Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004099486	A	20040402	JP 2002-261495	20020906
JP 4372398	B2	20091125		

PRIORITY APPLN. INFO.: JP 2002-261495 20020906
AB Title preps. are claimed. Title compound (I) may be in the form of liposomes, microspheres, or nanospheres. Thus, topical application of a solution containing I significantly lowered blood level of lipoperoxide in hyperlipidemic rabbits.

L13 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2004:709200 CAPLUS
DOCUMENT NUMBER: 142:49151
TITLE: Effect of Edaravone on Streptomycin-Induced Vestibulotoxicity in the Guinea Pig
AUTHOR(S): Horike, Osamu; Shimogori, Hiroaki; Yamashita, Hiroshi
CORPORATE SOURCE: Department of Otolaryngology, Yamaguchi University School of Medicine, Yamaguchi, Japan
SOURCE: Laryngoscope (2004), 114(9), 1630-1632
CODEN: LARYA8; ISSN: 0023-852X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB OBJECTIVES/HYPOTHESIS: The effect of topical administration of edaravone to the inner ear was investigated in guinea pigs with streptomycin-induced vestibulotoxicity. METHODS: Vestibulotoxicity was induced in 20 animals by delivery of streptomycin into the inner ear through osmotic pump for 24 h. Edaravone (n = 8, systemic administration group) or saline (n = 6, control group) was injected i.p. once a day for 7 days or edaravone-soaked Gelfoam was placed on the round window before wound closure (n = 6, topical administration group). RESULTS: Yaw head tilt and spontaneous nystagmus were observed in all animals after the operation. The number of spontaneous nystagmus beats in the topical administration group was statistically less than that in other two groups at 12, 18, and 24 h after the operation. CONCLUSION: The study results suggest that topical administration of edaravone better suppresses streptomycin-induced vestibulotoxicity than systemic administration.

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2003:97274 CAPLUS
DOCUMENT NUMBER: 138:153318
TITLE: Preparation of substituted phenols as cytoprotective agents useful in pharmaceutical and cosmetic formulations
INVENTOR(S): Wang, Bing; Zhang, Yong-Kang; Chen, Jian; Zhang, Wei; Song, Jiangao; Del, Balzo Ughetta; Brown, Lesley; Miller, Guy
PATENT ASSIGNEE(S): Galileo Laboratories, Inc., USA
SOURCE: PCT Int. Appl., 161 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent


LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003009807	A2	20030206	WO 2002-US23509	20020723
WO 2003009807	A3	20040429		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452159	A1	20030206	CA 2002-2452159	20020723
AU 2002319677	A1	20030217	AU 2002-319677	20020723
AU 2002319677	B2	20090326		
US 20030073712	A1	20030417	US 2002-202670	20020723
EP 1435894	A2	20040714	EP 2002-750281	20020723
R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505519	T	20050224	JP 2003-515200	20020723
JP 4425628	B2	20100303		
MX 2004000695	A	20050826	MX 2004-695	20040122
US 20050113416	A1	20050526	US 2004-15198	20041216
US 7629375	B2	20091208		
US 20050142155	A1	20050630	US 2005-55895	20050210
US 20060178356	A1	20060810	US 2006-387507	20060322
PRIORITY APPLN. INFO.:			US 2001-307439P	P 20010723
			US 2002-353702P	P 20020131
			US 2002-202670	A3 20020723
			WO 2002-US23509	W 20020723

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:153318

GI



AB Phenolic derivs. having conjugated bonds I [wherein R = NO₂, substituted alkenyl, or (un)substituted aryl(carbonyl), heteroaryl, or heterocycl; R₁-R₅ = independently H, carboxy, CN, halo, OH, NO₂, nitrone, sulfonate, or (un)substituted alkoxy(carbonyl), alkenyl, alkyl, or (hetero)aryl; or 2 adjacent members of R₁ to R₅ = O- and together complex with C or a metal; provided that at least 1 of R₁ to R₅ = MeOCH₂O or H(CH₂CMe=CHCH₂)_n; n = 1-4; further provided that when R₁ to R₅ = MeOCH₂O, R = Ph para-substituted by CN, NO₂, nitroso, NH₂OH, NH₂CO, alkyl ester, N-containing heterocycl, etc.; R₆ = H or (un)substituted alkoxy carbonyl; or stereoisomers or pharmaceutically acceptable salts thereof] were prepared as cytoprotective agents useful in pharmaceutical and cosmetic formulations.

For example, coupling of (4-nitrobenzyl)triphenylphosphonium bromide with 3,4-bis(methoxymethoxy)benzaldehyde using LiOEt in EtOH (41%) followed by deetherification with concentrated HCl in EtOH gave 4-[2-(4-nitrophenyl)vinyl]benzene-1,2-diol (81%). The latter was among invention compds. that showed significant reduction in edema in assays assessing rat paw edema (10 to 70%, p < 0.05) and mouse ear inflammatory response to topical arachidonic acid (15 to 80%, p < 0.05). Results from the neuronal cell stress assay and the rat middle cerebral artery occlusion model of cerebral ischemia were also disclosed for selected invention compds. Thus, I are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 15:57:48 ON 01 APR 2011)

FILE 'REGISTRY' ENTERED AT 15:58:00 ON 01 APR 2011
L1 1 S 89-25-8/RN

FILE 'CAPLUS' ENTERED AT 15:58:14 ON 01 APR 2011
L2 3315 S L1
L3 4 S L2 AND PERCUTANEOUS
L4 4 DUP REM L3 (0 DUPLICATES REMOVED)
L5 285 S L2 AND CEREBRAL
L6 1 S L5 AND (CROTAMITON)
L7 1 S L5 AND CROTAMITON
L8 1 S L5 AND "LACTIC ACID"
L9 15 S L2 AND "LACTIC ACID"
L10 0 S L9 AND CROTAMITON
L11 1 S L9 AND ISOPROPANOL
L12 9 S L2 AND (TOPICAL OR DERMAL)
L13 9 DUP REM L12 (0 DUPLICATES REMOVED)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.24	88.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.92	-13.92

STN INTERNATIONAL LOGOFF AT 16:04:49 ON 01 APR 2011